Investors

May 2017

MMJ Phytotech investor presentation May 2017

MMJ PhytoTech trades on the Australian Stock Exchange under the ticker code MMJ.

Current share price:

Cannabidiol capsules Phase 1 clinical trial published

Results from the Phase 1 Clinical Trial have been published.  The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology” has been published in an international, peer-reviewed medical journal, Clinical Pharmacology in Drug Development. This clinical trial was completed in March 2016, and demonstrated the […]

Posted in research notes |

Banyan Tree Investment Report on MMJ

In a new investment report, Banyan Tree Investment Group discusses key investment drivers for MMJ Phytotech and highlights the unique investment proposition the company offers to investors. Click here to read the full report. Facebook0Twitter0Google plus0Linkedin0X

Posted in research notes |

Phase 2 Epilepsy Clinical Trial Update

PhytoTech Therapeutics’ first Phase 2 clinical trial, which commenced in February 2017, is continuing as planned. This clinical trial is an open-label study aimed at evaluating the safety, tolerability and efficacy of oral administration of PTL101 as an adjunctive treatment for children with refractory epilepsy. The PTL101 drug beads are utilising proprietary formulation developed through […]

Posted in research notes |

Haywood Securities Research Report

Read the Haywood Securities investment report Facebook0Twitter0Google plus0Linkedin0X

Posted in research notes |
A list of the top 20 MMJ Phytotech shareholders is available here. The list will be updated quarterly.